Design of an international multicentre RCT on group schema therapy for borderline personality disorder by Wetzelaer, Pim et al.
Wetzelaer et al. BMC Psychiatry 2014, 14:319
http://www.biomedcentral.com/1471-244X/14/319STUDY PROTOCOL Open AccessDesign of an international multicentre RCT on
group schema therapy for borderline personality
disorder
Pim Wetzelaer1*, Joan Farrell2,3, Silvia MAA Evers4,5, Gitta A Jacob6, Christopher W Lee7, Odette Brand8,
Gerard van Breukelen9,10, Eva Fassbinder11, Heather Fretwell12,13, R Patrick Harper14, Anna Lavender15,
George Lockwood16, Ioannis A Malogiannis17,18, Ulrich Schweiger19, Helen Startup15, Teresa Stevenson20,
Gerhard Zarbock21 and Arnoud Arntz1,22Abstract
Background: Borderline personality disorder (BPD) is a severe and highly prevalent mental disorder. Schema
therapy (ST) has been found effective in the treatment of BPD and is commonly delivered through an individual
format. A group format (group schema therapy, GST) has also been developed. GST has been found to speed up
and amplify the treatment effects found for individual ST. Delivery in a group format may lead to improved
cost-effectiveness. An important question is how GST compares to treatment as usual (TAU) and what format
for delivery of schema therapy (format A; intensive group therapy only, or format B; a combination of group and
individual therapy) produces the best outcomes.
Methods/Design: An international, multicentre randomized controlled trial (RCT) will be conducted with a
minimum of fourteen participating centres. Each centre will recruit multiple cohorts of at least sixteen patients.
GST formats as well as the orders in which they are delivered to successive cohorts will be balanced. Within countries
that contribute an uneven number of sites, the orders of GST formats will be balanced within a difference of one. The
RCT is designed to include a minimum of 448 patients with BPD. The primary clinical outcome measure will be BPD
severity. Secondary clinical outcome measures will include measures of BPD and general psychiatric symptoms,
schemas and schema modes, social functioning and quality of life. Furthermore, an economic evaluation that consists
of cost-effectiveness and cost-utility analyses will be performed using a societal perspective. Lastly, additional
investigations will be carried out that include an assessment of the integrity of GST, a qualitative study on patients’
and therapists’ experiences with GST, and studies on variables that might influence the effectiveness of GST.
Discussion: This trial will compare GST to TAU for patients with BPD as well as two different formats for the delivery of
GST. By combining an evaluation of clinical effectiveness, an economic evaluation and additional investigations, it will
contribute to an evidence-based understanding of which treatment should be offered to patients with BPD from clinical,
economic, and stakeholders’ perspectives.
Trial registration: Netherlands Trial Register NTR2392. Registered 25 June 2010.
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Borderline personality disorder (BPD) is a common
mental disorder characterised by enduring and pervasive
patterns of instability in interpersonal relationships, iden-
tity, impulsivity, and affect [1]. The prevalence of BPD in
the general population, as revealed by recent community
surveys that use DSM-IIIR or DSM-IV criteria, is estimated
at 0.5 to 2.7% (median =0.7%) [2]. BPD prevents patients
from developing their full potential and leading a fulfilling
life. Consequently, many patients do not finish their
education, or complete it at a suboptimal level. Similarly,
many have a job beneath their capacity, or they have
no job at all. BPD patients often engage in problematic
relationships, self-injury, suicide attempts, and substance
abuse. Furthermore, 8-10% of BPD patients end their lives
prematurely due to suicide [3].
BPD severely impairs quality of life across mental, social
and physical dimensions [4]. In a Swedish study that
compared quality of life between women with BPD and a
normal population, it was found that women with BPD
were significantly impaired in all domains, including
physical, emotional, cognitive and sexual functioning
[5]. Relationships with their family and partner were
also found to be impaired [5]. Two Dutch studies have
shown that the burden of disease for both adolescent and
adult patients with various personality disorders, including
BPD, is severe and their quality of life is markedly
impaired [6,7].
In addition to the devastating effects of BPD on the
functioning of patients, it imposes a large burden on
their families, friends, and society as a whole. Families
and friends may face the challenging task of providing
informal care [8,9], whereas society bears the costs of a
more intensive use of health services [6,10-13], productivity
losses [10,13], and other inter-sectorial costs [14]. In clinical
settings, BPD patients are regarded as notoriously
difficult to treat, leading many therapists to refrain
from treating them. In the absence of robust evidence for
the effectiveness of any specific medication for BPD [15],
psychotherapy is, currently, the most promising strategy
for its treatment.
Schema therapy (ST) is delivered as an outpatient
treatment with the intention of bringing about full
recovery. It has proven more clinically effective than
transference-focused psychotherapy (TFP) in a random-
ized controlled trial (RCT) comparing both treatments
head-to-head [16]. Results from the same RCT also show
that it has a high probability of being more cost-effective
than TFP [17]. It was found that ST could be trans-
ported out of the clinical trial to use in the regular
Dutch healthcare setting with no loss of clinical effective-
ness [18]. In these studies, all treatments led to an
improvement in quality of life above and beyond recovery
from symptoms.ST can also be delivered in a group format, thus enabling
a more efficient use of resources. In addition, initial findings
have indicated that this format can increase the effectiveness
of ST [19]. Psychotherapy groups can provide a family-like
environment to patients, giving them a sense of belonging
and facilitating the secure attachments needed for limited
reparenting (a defining element of ST that refers to the
therapist trying, within the bounds of a professional rela-
tionship, to meet a patient’s unfulfilled core emotional
needs). Furthermore, patients can accept the responses of
peers as more ‘genuine’ than those of the therapist, whose
responses are, at least initially, often viewed as less ‘real’
and more professional. An RCT on group schema therapy
(GST) has demonstrated its effectiveness for the treatment
of BPD [19]. Treatment time in this study was relatively
short (eight months in contrast to up to three years for
studies on individual ST). This suggests that GST leads to
faster recovery than individual ST. However, this seminal
investigation still leaves important questions unanswered.
First, since this RCT was performed by the developers of
GST it is unknown how effective GST is when delivered by
other therapists in other centres. Second, in this RCT GST
was an addition to treatment as usual (TAU) for patients
who were already receiving TAU beforehand. GST has thus
not been tested as an integral and stand-alone treatment.
Third, this RCT was not accompanied by an economic
evaluation, and hence, does not give insight into the
cost-effectiveness of GST. Fourth, in this RCT TAU was
very ineffective. Because TAU has improved in recent years,
due to the dissemination of evidence-based treatments and
recent insights from studies, GST needs to be compared to
up-to-date TAU.
A second study on GST for BPD was a Dutch pilot study
in which two cohorts of BPD patients (total number of 18
patients) were treated with the combination of group and
individual ST [20]. This study showed large effect sizes on a
broad range of outcomes including improvements in BPD
symptomatology, general psychopathological symptoms
and quality of life. However, this study was uncontrolled
and also did not assess cost-effectiveness [20]. In sum,
findings on the clinical effectiveness of GST from previous
studies are promising yet leave open important questions
that need to be answered before the further dissemination
of GST is supported.
To answer these questions an international, multicentre
RCT on GST for BPD will be performed. This article
provides a description of the study design. The main
study objective is to compare the clinical effectiveness and
cost-effectiveness of GST and TAU. The RCT involves two
formats of GST, one that consists almost exclusively of
GST and one that combines GST with individual ST. Both
formats have a two year duration. Group and individual
schema therapy are, to a large extent, considered comple-
mentary and mutually supportive. Individual sessions may
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is in a better position to motivate a patient for treatment, to
offer extended trauma processing, and to offer a more in
depth attachment. In contrast, the group sessions may
provide important connection experiences that deal with
fundamental issues of BPD. For example, a stronger sense
of connection provided by the group may do more to
counter abandonment fears and sharing common experi-
ences among peers might add to a decrease in a patient’s
sense of isolation and/or defectiveness. On the one hand,
combining group and individual schema therapy may offer
potentially synergistic effects [20]. On the other hand,
the availability of individual sessions might lead to some
patients avoiding full participation in the group, thus
reducing its potential curative power. Hence, no specific
hypothesis about the superiority of either format has
been formulated. To evaluate the relative contribution of
the proposed formats to outcome, a secondary objective
is to compare the two formats of GST. This will help
to establish the optimal format for delivery of GST to
patients with BPD.
Furthermore, a series of additional substudies will be
performed. These consist of an assessment of the integrity
of GST, a qualitative investigation into the experiences of
patients and therapists with GST and an investigation of
variables that might influence the change process of GST
and thereby affect outcomes such as dropout rates and
patient improvement. Qualitative data will be collected
from patient and therapist interviews and/or focus groups
regarding their experiences of specific aspects of GST.
This will provide information on which aspects of the
GST protocol are most beneficial and any aspects that
may be less helpful or problematic. This will not only help
in identifying how the different components of ST can
affect outcome, but also in deciding which format is
preferred. Based on this information, GST can then be
further tailored to the needs of the primary stakeholders
before its further dissemination.
Methods/Design
In this RCT an evaluation of clinical effectiveness, a
full economic evaluation and a series of additional
investigations will be performed. Primarily, GST (format
A or B) will be compared to TAU and, secondarily, GST
formats A and B will be compared.
Design
A multicentre RCT will be conducted with participating
centres (at the time of this writing) in the following
countries: six centres in the Netherlands, three in
Germany, one in Australia, two in the UK, one in the USA
and one in Greece. Some centres that initially agreed to
participate had to withdraw because of budget cuts
resulting from economic difficulties that made participationimpossible. One Dutch centre withdrew due to recruitment
rates being too slow and was replaced by another centre. In
contrast, two Dutch centres’ expeditious recruitment
rates permitted the inclusion of a third cohort. This
can compensate for additional centres that agreed to
participate but may still withdraw, or for centres that
fail to recruit the planned minimum of 32 patients
per centre. Patient flow, screening, randomization and
assessments are displayed schematically in Figure 1. The
research protocol has been approved by the Medical
Ethics Committee of Maastricht University for the Dutch
sites; by the Murdoch University Human Research
Ethics Committee for the Australian sites; by the Ethics
Committee of the Albert-Ludwigs-University Freiburg, the
Ethics Committee of the University of Lübeck and the
Ethics Committee of the Psychotherapist Association
Hamburg for the German sites; by the Ethics Committee of
the Eginition Hospital, Medical School, University of
Athens for the Greek site; and by the National Research
Ethics Service Committee London - Camberwell St Giles
for the British sites. Ethical review is in process in the USA.
Recruitment
Patients will be recruited in the participating centres. They
will be invited to participate in the screening process when
diagnosed with BPD or when this is suspected. Both
patients who are already receiving treatment for BPD as
well as new referrals can be included as participants. After
reading and hearing information on the RCT and signing
an informed consent, patients will be assessed for in- and
exclusion criteria.
Patients
Patients are eligible when they (1) are between 18 and
65 years of age, (2) have a primary diagnosis of BPD, (3)
have a BPD severity score of above 20 on the Borderline
Personality Disorder Severity Index, version IV [21], (4)
are willing to participate in the study and (5) are able to
participate in (group) treatment and research for 2 years.
Patients will be excluded if they have a lifetime psychotic
disorder (except for a brief psychotic disorder as
described in the Diagnostic and Statistical Manual of
mental disorders, version IV (DSM-IV) BPD criterion 9);
an IQ below 80; if they are unable to read, speak or write
the language used at the centre; if they have Attention
Deficit Hyperactivity Disorder (ADHD) (if successfully
treated, ADHD is not an exclusion criterion), bipolar
disorder type 1, dissociative identity disorder, full or sub
threshold narcissistic or antisocial personality disorder
(PD), substance dependence needing clinical detoxification,
a serious and/or unstable medical illness or if they have
received schema therapy of more than three months
duration in the last three years. Well-trained clinicians will
diagnose patients at baseline using Structured Clinical
Figure 1 Flow chart of the study design. Patients with BPD are recruited at 14 participating centres and screened for eligibility. After informed
consent is signed, baseline assessments are performed. Subsequently, patients are randomized in blocks of two per centre to either GST or TAU. Half
of the centres offer GST-A to the first cohort of patients and the other half offers GST-B to the first cohort of patients. In two Dutch sites, a third cohort
is recruited which is randomly assigned to either format for GST so that the total number of cohorts receiving both formats is balanced. Assessments
are performed approximately every six months for the first two years, after which GST treatment ends. Costs are also assessed at approximately
30 months. Follow-up assessments take place 36 months after randomization.
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II). Screening for ADHD will be performed using a six item
version of the World Health Organization (WHO) ADHD
screener [22]. If this screener indicates the presence of
ADHD, then the patient will be further assessed with the
ADHD section of the Structural Clinical Interview for
DSM-IV, Childhood Diagnosis (KID-SCID) to examine
whether ADHD was present during primary school age to
exclude false positives.Sample size
Previous findings of Farrell et al. [19] indicate an outcome
difference between GST and TAU with an effect size of d
around 2 (d refers to Cohen’s d [23]). However, some
shrinkage of the effect might be expected when GST is pro-
vided by centres that were not involved in the development
of GST. Also, although TAU was virtually ineffective in the
abovementioned study, recent meta-analyses and RCTs of
modern treatments for BPD suggest that these treatments
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to have sufficient power to detect an effect size of d = 0.5.
With respect to the comparison between the two
formats for GST, no large outcome differences are expected.
Whereas small differences are unlikely to influence the pref-
erences of patients and therapists, medium differences may.
Therefore, sufficient power is needed to detect an effect size
of d = 0.5 between the two formats of GST.
Over the course of three years a dropout of 20% is
expected, with about 5% in the first year. Assuming
the effects of GST and TAU become apparent after one
year [19], the study is powered taking into account a 5%
attrition rate. Later attrition is partly compensated by
including all randomized patients in analysis. Furthermore,
since conservative effect sizes were chosen, the calculated
initial sample size could be larger than needed and may
therefore also compensate for attrition over 5%.
To test whether GST is superior to TAU and assuming
centre as random effect and a centre by treatment inter-
action that corresponds to a typical intraclass correlation
coefficient (ICC) of almost 0.05 in line with literature
[26,27], 236 patients (which implies 8 centres of 32
patients, 16 receiving TAU and 16 receiving GST) are
needed to detect a difference of d = 0.5 with 90% power
using a two-tailed significance level of α = 0.05. For
the comparison between GST-A and GST-B and again
assuming a typical intraclass correlation of nearly
0.05, a sample size is needed of 202 patients (which
implies 13 centres of 16 patients, 8 receiving GST-A
and 8 receiving GST-B) to have 90% power to detect
a difference of d = 0.5 at a two-tailed significance level of
α = 0.05. Taking into account the expected 5% attrition,
one additional centre is needed. To be able to balance the
orders in which GST formats are delivered to successive
cohorts, an even number of sites is required. Including 14
centres gives 90% power to detect a difference of d = 0.40
between GST and TAU and a difference of d = 0.50
between GST-A and GST-B, both at a two-tailed signifi-
cance level of α = 0.05 (a detailed explanation of the sample
size calculation is provided in Additional file 1).
Randomization
Patients will be randomized centrally in blocks of two per
centre (GST versus TAU) using a computer-generated list
by an independent central research assistant after baseline
screening is complete and all in/exclusion criteria have
been checked by this assistant. Each centre will have at
least two cohorts of at least sixteen patients of which eight
are randomized to GST and eight to TAU. In half of the
centres the patients from the first cohort will be randomized
to GST format A, which is an intensive group treatment
or TAU. The patients from the second cohort will be
randomized to GST format B, which combines individual
and group treatments or TAU. In the other half of thecentres the first cohort will be randomized to GST-B or
TAU and the second to GST-A or TAU. The GST
formats as well as the orders in which they are delivered
to successive cohorts (first GST-A versus TAU, then
GST-B versus TAU, and vice versa) will be balanced.
Within countries that contribute an uneven number
of sites, the numbers of orders of GST formats will
have a difference of one.
Assessments
Prior to randomization, patients will be assessed at baseline.
Baseline assessments will be spread over a period of
approximately three months on average. Once a cohort is
nearly complete, baseline assessments can be speeded up
so they are completed within a minimum time period of
one month. Inversely, when inclusion is too slow, the
maximum time period patients are required to wait
before treatment will start is limited to one year. When
baseline assessments are complete for all patients, patients
will be randomized and treatment will start. Subsequently,
patients will be re-assessed approximately every six months
over the course of two years. Since the treatment duration
for GST is also two years, the fourth assessment after
baseline will coincide with GST treatment ending.
Follow-up assessments will take place one year later. For
the cost interview, a recall period of a year is considered
too long. Therefore, an additional assessment will take
place midway during the follow-up time period (i.e. two-
and-a-half years after start of treatment) during which
only the cost interview will be performed.
All assessments will be performed by local research
assistants in the centres, except for SCID-interviews which
will be done by trained interviewers blind for condition.
Assessments include PC-based self-report questionnaires
and interviews. An overview of the instruments used per
assessment is provided in Table 1.
At baseline, the Interview for Traumatic Events in
Childhood (ITEC) will be conducted. This is a retrospective,
semi-structured interview for childhood maltreatment in-
cluding sexual, physical and emotional abuse and physical
and emotional neglect [28]. At follow-up, patients are
assessed for recovery from BPD as well as the most
common comorbidities by trained interviewers using
the following sections of SCID-I for DSM-IV-Tr:
affective disorders (including bipolar disorder I and II),
anxiety disorders, eating disorders and substance disorders;
and the following sections of SCID-II for DSM-IV-Tr:
avoidant, dependent, obsessive-compulsive, paranoid,
schizotypal, schizoid, histrionic, narcissistic, antisocial
and borderline PD. Since only current diagnoses need to be
considered for the assessment of recovery from BPD and
comorbidity, the recall period for these shortened SCIDs is
limited to six months. Only when a patient will otherwise
become a study dropout (e.g. due to unwillingness to come
Table 1 Instruments used per assessment
Screening Baseline* 6 months 12 months 18 months 24 months 30 months 36 months
SCID I • •
SCID II • •
WHO ADHD screener •
ITEC •
BPDSI-IV •• • • • • •
GAF •• • • • • •
SOFAS •• • • • • •
BPD checklist • • • • • •
WSAS • • • • • •
BSI • • • • • •
YSQ-short form • • • • • •
SMI • • • • • •
RSQ • • • • • •
ECNI • • • • • •
EuroQol-5D • • • • • •
WHOQOL-short version • • • • • •
Cost interview • • • • • • •
Abbreviations: SCID I Structured Clinical Interview for DSM-IV Axis-I Disorders, SCID-II Structured Clinical Interview for DSM-IV Axis-II Disorders, WHO ADHD World
Health Organization Attention Deficit Hyperactivity Disorder, ITEC Interview for Traumatic Events in Childhood, BPDSI-IV Borderline Personality Disorder Severity
Index version IV, GAF Global Assessment of Functioning, SOFAS Social and Occupational Functioning Assessment Scale, BPD Borderline Personality Disorder,
WSAS Work and Social Adjustment Scale, BSI Brief Symptom Inventory, YSQ Young Schema Questionnaire, SMI Schema Mode Inventory, RSQ Relationships Scales
Questionnaire, ECNI Emotional Core Needs Inventory, EuroQol-5D European Quality of Life questionnaire-5 dimensions, WHOQOL World Health Organization Quality
of Life questionnaire. *Baseline consists of five assessments and BPDSI, GAF and SOFAS are assessed twice at baseline.
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at home. Interviews are then conducted by telephone. By
doing so, the occurrence of missing data will be reduced.
Due to the nature of the study, blinding of participants is
not possible. Except for the cost interview, which contains
specific questions on which treatments patients have
received, assessments will be performed by blinded local
research assistants. The cost-interview, containing ques-
tions on health care utilization that would unblind the
condition will be done by a nonblinded research assistant.
This assistant will also monitor treatments provided in
TAU. Furthermore, this nonblinded research assistant will
collect treatment session recordings that are needed for
supervision and validation of treatment adherence. After
checking the quality of the recording, the sample of
recordings that is needed will be stored.
To maximize adherence to the study protocol, a manual
has been created for all local research assistants. A central
research assistant is appointed to whom local research
assistants can address questions concerning any logistical
issues. This individual will also perform checks and
provides guidance and direction when needed. Checks
include study protocol adherence, in- and exclusion
criteria of candidate participants, and keeping track of
the scheduling and advancement of assessments, data
and the collection of audio and video recordings. Thecentral research assistant will furthermore train local
research assistants, distribute the instruments used for
assessments, provide updates of the manual, explain data
format requirements, and prepare the online data collection
environment. In sum, the central research assistant will
safeguard the validity of assessments.
Treatments
Group schema therapy
Schemas refer to the knowledge representations people
have about themselves, others and the world and which
are formed during childhood by the way basic needs are
met. When a child has to cope with his or her basic
needs not being met, a variety of dysfunctional schemas,
and/or coping styles, may develop. Schema modes refer
to the emotional states between which BPD patients can
rapidly switch when triggered by events that are related
to the unmet needs during childhood. Schema modes
represent sets of schemas and/or coping styles that are
typically expressed in such emotional states. The following
schema modes are characteristic for BPD: the vulnerable
(abandoned/abused) child, angry/impulsive child, punitive
parent, detached protector (or any other protective mode),
healthy adult and happy or contented child. The first four
of these modes are maladaptive and strongly present in
BPD patients. The latter two are functional modes and
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maladaptive modes and develop and strengthen functional
modes [29]. This schema mode model guides therapy as
each mode requires a different treatment strategy. The
strategies comprise specific experiential, cognitive and
behavioural techniques [30]. When offered in a group
format, several factors may amplify and speed up recovery:
peer support, a sense of belonging and understanding,
opportunities for vicarious learning and real-life practice
of healthy behaviour [19].
In format A (GST-A), two-year GST consists of 124
groups sessions with a duration of 90 minutes. In the
first year group sessions take place twice a week and in
the second year the frequency gradually decreases. In
addition, in GST-A a total of up to 18 individual sessions
can be used at the patients discretion or in times of crisis.
Two individual sessions take place before group sessions
commence. At this time patients get acquainted with their
group schema therapists, schema therapy and the schema
mode model are explained, the schema modes a patient
has and their relationship to one another are identified
and a treatment plan is drawn up.
In format B (GST-B), two-year GST involves a
combination of group and individual sessions. In the
first year, there are weekly group sessions of 90 minutes
and individual sessions of 50 minutes and in the second
year the frequency gradually decreases. In total, patients in
this condition receive 74 group sessions and 62 individual
sessions. In the first two individual sessions patients get
acquainted with their individual and group therapists,
schema therapy and the schema mode model are explained,
the schema modes a patient has and their relationship to
one another are identified and a treatment plan is drawn
up. Group and individual ST therapists meet regularly to
coordinate treatments.
Treatment as usual
Following usual procedures, the intake staff at each centre
determine the optimal treatment offered to each patient in
the TAU condition. Except for (G)ST, the intake staff are
allowed a choice from the whole array of possible
treatments for BPD with no restriction; whether intensive,
individual, group, inpatient, outpatient or day treatment.
The TAU condition is thus representative of optimal
current practice and will be carefully monitored for all
patients. Since there is no protocol for TAU in this RCT
and specific treatment is decided on by experts in
the community treatment centre, TAU is equivalent to
‘community treatment by experts’.
In some centres, the treatment that is usually offered
to BPD patients is Dialectical Behavioural Therapy (DBT).
This is an empirically validated treatment for BPD
[24,31]. If the number of centres that offer DBT as
the usual treatment is sufficient, this will provide anopportunity to compare the clinical effectiveness and
cost-effectiveness of GST with DBT.
Therapists, training and supervision
GST sessions are run by two schema therapists, of whom
at least one is a senior schema-therapist. Stand-in
schema therapists replace the regular therapists when they
are absent (e.g. due to illness, holidays or pregnancy). The
senior therapist’s role, in addition to being a group schema
therapist, is to act as a local supervisor for other schema
therapists. Individual schema therapists can also be group
schema therapists for GST. Group schema therapists
receive a training of six days in GST [32]. Candidate ST
therapists (individual and group) who are not yet trained
in ST first receive a 3–4 day training in individual ST for
BPD [33]. During the study intensive supervision meetings
are held twice a year in the first year and once or
twice a year in the second year. In addition, weekly team
supervision is provided locally and central supervision
by the developers of GST is provided through teleconfer-
encing and viewing of video-recordings weekly in the first
months, then biweekly and monthly after about 6 months.
Initially, a computer program was acquired that was
especially designed to enable secure online sharing of
video-recordings of medical procedures through encrypted
streaming. Unfortunately, this program has become
unavailable. The encrypted recordings will now be uploaded
on a central server so that supervisors can download and
watch them.
Evaluation of clinical effectiveness
In this section, the primary and secondary clinical out-
come measures that will be used to evaluate the clinical
effectiveness of the treatments are described as well as
the strategy used for analysis of the data. All instruments
that will be used to investigate clinical effectiveness that
were not yet available in the languages of all participating
sites were translated. Translated versions were back-
translated and thoroughly checked for consistency with the
original version. Any inconsistencies were addressed in
consensus meetings and adjusted accordingly. Instruments
are implemented in an online data collection environment.
Clinical outcome measures
Borderline Personality Disorder Severity Index version IV
(BPDSI-IV)
The primary outcome measure is the severity of BPD,
expressed as a score between 0 and 90 as measured
with the Borderline Personality Disorder Severity Index
(BPDSI), version IV. The BPDSI-IV is a semi-structured
interview containing 70 items based on the nine BPD
dimensions described in DSM-IV. This is a reliable and
valid instrument, suitable for use as an outcome measure
[21,34]. A cut-off score of 15 between patients and controls
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below 15 measured two years after randomization or earlier
and maintained until follow-up can be used as a criterion
for recovery. The scores on subscales of the BPDSI-IV
provide information on the severity of each of the nine
dimensions of BPD. The recall period for the BPDSI-IV is
three months.
BPD checklist
The BPD checklist is a self-report instrument that measures
the burden of BPD manifestations as experienced by patients.
Since the BPD checklist measures changes in subjective bur-
den, it is complementary to the BPDSI-IV that measures
changes in symptomatology objectively. It consists of 47
items based on the nine dimensions of BPD in DSM-IV and
answers are scored on a five point Likert scale. Suitability for
use as a treatment outcome measure has been established
[35]. The recall period for the BPD checklist is one month.
Brief Symptom Inventory (BSI)
The BSI is a self-report instrument used as an inventory
of general psychiatric symptoms present at the time of
assessment and is a short alternative to the SCL-90-R,
from which it was developed [36]. It contains 53 items to
inventory the following nine types of primary symptom
dimensions: somatic, cognitive, inter-personal sensitivity,
depressive mood, anxiety, hostility, phobia, paranoia and
psychoticism. Answers are scored on a 5-point Likert
Scale. Cronbach’s α is .96 for the instrument in total
and ranges between .71 and .87 for its subscales [37].
According to [38], Cronbach’s α values of 0.9 or higher
indicate an internal consistency that is appropriate
for clinical applications, and values of 0.7 to 0.8 are
satisfactory for comparing groups. In addition, the BSI has
good discriminant validity [37].
Happiness item
The happiness item is a single question on general
happiness in the months prior to the assessment and is
scored on a seven point Likert scale [39]. This scale consists
of the following verbal descriptions of different states of
happiness: (1) completely unhappy, (2) very unhappy, (3)
fairly unhappy, (4) neither happy nor unhappy, (5) fairly
happy, (6) very happy, (7) completely happy. Norms for
all participating countries are available [39]. For a single
happiness item high test-retest reliability (r = 0.86) and
good concurrent, convergent, and divergent validity have
been reported [40]. The happiness item has excellent
sensitivity to change for patients with BPD who were
treated with GST [20].
Schema Mode Inventory (SMI)
The SMI is a self-report instrument that consists of 143
items on 16 schema modes that are scored on a six pointLikert scale. It measures the extent to which dysfunctional
as well as functional schema modes are present at the time
of assessment [41]. It is an adaptation of the original SMI
containing 270 items [42] and short SMI containing 118
items [43]. This instrument is only used for patients
in the GST condition. Its subscales have satisfactory
to high internal consistency (Cronbach’s α ranges from .79
to .96) [43]. The SMI is a useful instrument for assessing
modes in ST [43].
Young Schema Questionnaire – short form (YSQ)
The YSQ is a self-report instrument containing 75 items
that are scored on a six point Likert scale [44]. It is used to
measure the presence or absence of 16 core maladaptive
schemas at the time of assessment. The YSQ has adequate
temporal as well as rank-order stability and an analysis of
its discriminant power in clinical versus non-clinical
samples revealed it is highly sensitive in predicting the
presence or absence of psychopathology [45]. Internal
consistency is high for the overall scale (Cronbach’s α ranges
from .94 to .96) and satisfactory to high for its subscales
(Cronbach’s α ranges from .72 to .94) [46].
Global Assessment of Functioning (GAF) and Social and
Occupational Functioning Assessment Scale (SOFAS)
Based on axis V of DSM-IV, the GAF and SOFAS are 100-
point scales used to assess general and social/occupational
functioning, respectively. A short semi-structured interview
serves to elicit the information needed for scoring.
The recall period for both instruments is one month.
The GAF is a valid scale of global psychopathology
and the SOFAS is a valid measure of social, occupa-
tional and interpersonal functioning [47]. Both instruments
have excellent interrater reliability (intraclass correlation
coefficients > .74) [47].
Work and Social Adjustment Scale (WSAS)
The WSAS is a self-report instrument that consists of 5
items that are scored on a scale ranging from 0 to 8. It is
used to assess functional impairment at the time of
assessment in the domains of work, household, social
leisure, private leisure and family and relationships. The
WSAS’ reliability, validity and sensitivity to change have
been firmly established in samples of patients with different
clinical disorders [48-50].
Relationship Scales Questionnaire (RSQ)
The RSQ was designed as a continuous measure of adult
attachment and consists of 30 short statements about
romantic relationships [51,52]. After being instructed to
think about such relationships in their past and present
lives patients rate the extent that these statements
resemble their own feelings and experiences at the
time of assessment on a five point Likert scale. Scores
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secure, dismissive, fearful and preoccupied.
Emotional Core Needs Inventory (ECNI)
The ECNI is a list of 88 statements used to measure the
extent to which basic needs are being met in important
relationships at the time of assessment [53]. Each statement
is rated on a scale ranging from 1 to 6. A higher rating
corresponds to better need-fulfilment. Assessing the extent
to which patient’s needs are met by others is important
given that maladaptive schemas are hypothesised to result
from unmet core emotional needs. A central aim of ST is
to bring about changes that lead to better need-fulfilment
of patients [54].
World Health Organization Quality of Life questionnaire
(WHOQOL-short)
The WHOQOL-short is a self-report instrument for asses-
sing quality of life in the two weeks prior to assessment. It
is a short version (35 items) of the WHOQOL and focuses
on the domains of physical health, psychological health,
social relationships, environment, positive feelings, negative
feelings and self-esteem. The WHOQOL-short is a reliable
and valid instrument [55].
Analyses
All available data on clinical outcomes will be analysed
according to the intention-to-treat principle. Outcome
measures will be analysed with mixed regression, also
known as multilevel or hierarchical regression, with centre
as a random effect, allowing centre by treatment inter-
action, and including patient-level and treatment indicator
covariates, as well as time and treatment by time effects.
Baseline covariates will be used to adjust for potential
differences at baseline and to reduce standard errors. For
categorical outcome variables, counts and in case of non-
normal residuals, appropriate forms of mixed regression
will be chosen (binomial, Poisson, gamma, etc.).
Economic evaluation
The following section describes how costs and utilities
will be measured for the economic evaluation as well as
the planned cost-effectiveness and cost-utility analyses.
The cost interview has been translated into the lan-
guages of all participating sites. The original Dutch ver-
sion was first translated to English and subsequently
this English version was then translated into Greek
and German. The translated versions have been back-
translated and/or thoroughly checked for consistency
with the original version. Any inconsistencies were
addressed in consensus meetings and adjusted accord-
ingly. The cost interview will be implemented in an online
data collection environment.Costs measurement
Costs will be measured from a societal perspective using
a retrospective cost interview especially designed for
BPD patients. Relevant costs to be identified include
healthcare, patient and family costs, and costs outside
the health care sector. Healthcare costs include visits
to general practitioners, hospitals, psychiatrists and
psychologists, crisis centres, use of medication, social
work, formal care, and alternative treatments. Patient
and family costs include travelling costs, informal care
(care provided by family, friends or neighbours of the
patient) and out of pocket costs (alcohol, drugs, smoking
and self-reported other costs). Costs in other sectors
include productivity losses from unpaid work (voluntary
work and study) and paid work. The cost interview will be
conducted by trained local research assistants, who will
ask questions on the consumption of different resources
and assess volumes of resource use. When applicable,
calculations and descriptive content will be noted. For the
cost interview the recall period is 6 months.
Utility measures
EuroQol-5D-3 L (EQ-5D-3 L)
The EQ-5D-3 L is a generic, self-assessment instrument
used for measuring health-related quality of life at the time
of assessment [56]. It consists of five questions, each related
to a specific dimension of health status: mobility, self-care,
usual activity, pain/discomfort and anxiety/depression.
The EQ-5D has been translated in the languages of all
participating sites [57]. The descriptive profiles, generated
by the EQ-5D-3 L are valued using social tariffs for the
EuroQol to generate utilities, which reflect a population’s
preference for a particular health profile.
In base-case analysis, country-specific tariffs will be used
for valuation when available. For the Netherlands, Germany
and the UK national tariffs are available, whereas for Greece
and Australia they are not [57]. For these countries, proxy
tariffs will be used as an alternative (e.g. tariffs for Europe
and New-Zealand, respectively). Sensitivity analyses will be
performed that make use of country-specific tariffs for the
valuation of health profiles of all patients.
Utilities will be used to calculate Quality Adjusted Life
Years (QALYs) by multiplying change in utility between
assessments by the duration of the time period between
assessments. Through the use of statistical regression,
potential baseline differences in QALYs can be adjusted
for [58].
In addition, the EuroQol thermometer will be scored
in a range between 0 and 100 to provide a single index
measure for a patient’s health status [56].
Analyses
The economic evaluation will be comprised of both a
cost-effectiveness analysis (CEA) and cost-utility analysis
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All available data on costs and outcomes will be analysed
according to the intention-to-treat principle. Data gathered
with the cost interview will first be checked for adherence
to questionnaire routing, illogical answers, unrealistic cost
estimates and outliers. For any problems in the data that
cannot be solved through logic, decision rules will be
established. A decision rule could apply a specific limit to
volumes of costs, e.g. the maximal hours patients spend
per day on caring for their children can be limited to eight
for patients who report doing this for 24 hours per day.
For intermittent missing values at the item level of the cost
interview the mean values of previous and subsequent
assessments will be imputed to allow calculation of total
costs. Missing values on total scores or other outcomes will
not be imputed. Unrealistic or extreme values will be
investigated per case and corrected when appropriate.
Volumes of resource use as measured by the cost interview
will be multiplied by their corresponding unit costs and
then summed to provide an overall total cost. Unit costs
will be based on standard unit prices for each country
(e.g. in the Netherlands: Hakkaart-van Roijen et al. [59]
for cost prices of healthcare services [59]) when available
and on (averaged) tariffs otherwise. Cost prices will be
expressed in Euros for the same base year and indexed
using consumer price indices when required. Cost prices
expressed in currencies other than Euros will be converted
using purchasing power parities. In addition, to account
for the three year time horizon of this RCT, cost prices
will be discounted according to the guidelines. When
neither standard unit prices nor tariffs are available
for specific resource items in specific countries, alternative
strategies for the valuation of resource use will be consid-
ered. When for a subset of resource items the unit costs are
known in all countries and for all other resource items there
is a unit cost available in at least one country, the
unit cost of a resource item that is not available in
one or more countries can be estimated through a
procedure called market-basket based imputation [60].
In base-case analysis, country-specific unit costs will be
used to value resource use for each country. Sensitivity of
the results to differences in unit prices between countries
will be analysed by valuing resource use in all countries
using unit prices of a single country. Productivity losses
will be valued by the human capital approach through
multiplication of the total number of hours lost with the
national average hour wage. Shadow prices will be used to
value informal care and lost productivity in study and
voluntary work. The primary clinical outcome for the
CEA will be the BPD Severity Index (BPDSI) score and for
the CUA primary utility scores will be derived from the
EuroQol-5D. Cost-effectiveness and cost-utility data will
be analysed with multilevel modelling techniques. The net
monetary benefit will be used to express cost-effectiveness,and results will be expressed in cost-effectiveness accept-
ability curves. Net monetary benefit (NMB) will be
calculated for a range of values for the amount decision
makers are willing to pay (WTP) for an additional unit of
effect, following: NMB =ΔE*WTP- ΔC, where ΔE is the
difference in effects and ΔC is the difference in costs [61].
To accommodate the skewness that is typically observed
in cost data, costs (or NMB) can be assumed to follow a
gamma or log-normal distribution. Baseline covariates will
be used to adjust for potential differences at baseline and
to reduce standard errors. Results will be expressed in
cost-effectiveness acceptability curves that display the
probability, based on the available evidence, that GST can
be considered cost-effective for a range of WTP values.
For these types of analyses, a Bayesian approach is the
most natural, since it allows direct and intuitive
statements to be made regarding the probability that
a treatment is cost-effective, based on the available
evidence [62]. Furthermore, Bayesian methods allow
flexible joint modelling of costs and effects, thereby facili-
tating sensitivity analyses regarding different methodo-
logical approaches for specification and parameterization of
the model. Sensitivity analyses will be performed to address
uncertainty regarding methodology, model specification
and prior distributions.
Additional substudies
Complementary to effectiveness and cost-effectiveness
evaluations, a series of additional investigations will be
performed that consist of an assessment of the integrity
of GST, an investigation into the opinions of primary
stakeholders and additional studies that examine vari-
ables that might mediate the change process in GST.
Treatment integrity
Adherence to GST treatment protocol will be assessed by
trained independent judges who rate a random selection of
video-recordings of group-ST using a newly developed
instrument. For individual ST, a random selection of
video-recordings will be rated using existing instruments
[16,63] by trained raters. As sampling recordings of TAU
will be impossible in many sites, due to ethical and
logistic reasons (e.g. TAU in private practice or TAU
in mixed groups including patients not participating), the
differentiation between ST and TAU will be assessed by
having patients fill out a checklist with techniques that are
typical for ST and non-typical for ST.
Patient and therapist perspectives
This study involves the acquisition of qualitative data in the
form of patients’ and therapists’ opinions about treatment
and the preferred format for GST. The opinions of these
major stakeholders will be elicited through in-depth inter-
views and/or focus groups, allowing them to share their
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GST. Topics include which aspects of the GST protocol are
perceived to be beneficial or not, application of specific ST
techniques, therapeutic relationships and therapist training
and supervision. Saturation is expected to be reached after
having interviewed 12 GST patients in each participating
country and 12–15 therapists, after which assessment will
be discontinued. The centres that participate in this aspect
of the study are from the Netherlands, Germany and
Australia. Centres in other countries might decide to
participate later. Patients will be sampled from both GST
formats and from 3 phases of treatment: first year, second
year, and after treatment completion. All interviews are
recorded. After a full transcription of the recordings is
made a summary is made. This summary is then reviewed
by patients and therapists as a check on its veracity. If
needed, the summary will be corrected to be sure that the
verbatim transcripts express patient and therapist opinions
correctly. Verbatim transcripts of interviews with patients
and therapists will be analysed for their content using
specialized software. Important and/or recurring themes
will be categorized, interpreted and reported.
Studies on variables affecting treatment outcomes
The final area for additional investigation is the extent that
patient variables affect outcomes such as dropout rates and
patient improvement. This includes genetic polymorphisms,
dissociation, comorbidity, individual patient trajector-
ies, change processes and the therapeutic relationship,
changes in neural correlates of emotional sensitivity,
regulation and impulsivity during treatment, changes in
threat bias during treatment, changes in needs during
treatment, somatic symptoms and somatization, the thera-
pist’s voice and use of recordings for secure attachment,
the effects of training, early self-understanding as a pre-
dictor for outcome, the effect of treatment on comor-
bidity and changes in attachment representation.
Discussion
In this article the design is described for an international,
multicentre RCT on GST that includes an evaluation of the
clinical effectiveness, a full economic evaluation as well as a
series of additional investigations. In this RCT, GST (format
A and B) will be compared against optimal TAU in terms
of clinical effectiveness and cost-effectiveness. Such a design
follows the ‘gold standard’ in cost-effectiveness research
[64] and allows us to investigate whether GST excels
current practice, which consists of the existing optimal
treatments that are usually provided to patients with BPD.
TAU consists of a variety of different treatments due to the
fact clinical practice varies between centres as well as
between countries. Since TAU is tailored to the individual
needs of each patient, it can be considered representative of
optimal current practice. The multicentre and internationaldesign of this RCT specifically intends to capture the
variation in clinical practice between participating
centres and between countries, respectively. Because
the resulting amalgam of treatments in TAU reflects
current practice, external validity is increased. If the RCT
was designed to include a fixed treatment instead of
variable TAU as a comparison to GST, then it would be
less informative in regard to whether GST excels current
practice and whether its further implementation is
supported. Furthermore, if the RCT was designed as
a head-to-head comparison between GST and another
experimental treatment without the inclusion of TAU,
then interpretation of its results could be hindered. This is
because it is not clear how experimental treatments
compare to TAU. For instance, experimental treatments
might do worse than or be equivalent to TAU. For these
reasons, TAU is considered to be an appropriate comparator
to GST at this stage of research. However, with this TAU
there is little control over the specific issues that are
addressed in therapy, the amount of attention a patient
receives and the frequency of therapeutic contacts. It is
therefore less rigorously defined than the experimental
condition. In addition, therapists providing TAU may not
receive the intensive supervision that GST therapists receive
and the treatment fidelity of the components of TAU is not
monitored. These issues could be a potential threat to
internal validity [65]. Notwithstanding, TAU will be
delivered by skilful therapists with extensive experience in
the treatment of BPD and its contents are monitored by
administering a questionnaire on the specific treatments
that each patient receives.
The fact that this RCT will take place with multiple par-
ticipating centres and in an international context has spe-
cific advantages and disadvantages. Several advantages of
international clinical trials over single-country trials have
been formulated [66], which also hold in the case of multi-
centre trials versus single centre trials. First, in multicentre
or international RCTs, through parallel recruitment of
patients at the different sites, it takes less time to include a
sufficient number of patients in comparison to single site
studies. Second, the representativeness of the study popula-
tion is enhanced by capturing more of the variability in
patient characteristics, clinical practice patterns and/or
health care systems. Third, the collection of data at multiple
sites enables the researcher to inform decision makers in all
of the participating sites.
Paradoxically, whereas the inclusion of more variability
enhances the representativeness of the study population, this
same variability makes it difficult to apply the results to any
one centre or country in particular. In other words, studies
designed to include multiple participating centres and/or
countries raise issues concerning their generalizability
[67,68]. At the patient level, variation between sites exists in
terms of demography and epidemiology. At the level of
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in patient management. Differences between healthcare
systems and other socioeconomic factors may influence
healthcare delivery and the allocation of scarce resources to
healthcare, respectively. Inversely, some degree of similarity
within healthcare systems, treatment centres or patients
may also be expected. A method that can accommodate
the hierarchical structure of such data is multilevel model-
ling, which has been proposed as an appropriate analytic
strategy for cost-effectiveness data from multinational RCTs
[67-70]. It allows variation to be estimated within and
between the different levels. Moreover, these estimates can
be used to calculate centre-specific estimates of cost-
effectiveness [67], which can be used to determine the
extent to which the results from this RCTare generalizable.
Since this RCT involves multiple participating centres in
different countries, organizational and logistical challenges
potentially threaten its quality. Handling these challenges
is a labour-intensive process that requires thoughtful plan-
ning, a clear protocol, continuous monitoring of protocol
adherence, and well-defined communicational lines. The
hub in the logistical infrastructure is a central research
assistant who will perform checks and steering con-
cerning study protocol adherence and therefore plays an
important role in ensuring the validity of the assessments.
Organizational issues may arise when, for example, thera-
pists, coordinators or research assistants retreat from the
study and are replaced, when recruitment rates are slower
than was foreseen or video-facilities for treatment supervi-
sion are missing. The appropriate handling of these issues
requires timely noticing of their occurrence, which will be
facilitated by regular internet conferences involving the
principal investigators and local coordinators.
In this RCT, both primary and several secondary clinical
outcome measures will be assessed through interviews.
Therefore, it is necessary to control interviewer bias by
having blinded interviewers perform the assessments. For
interviews containing specific questions about which
treatment the patient receives (the cost interview and
the monitoring of treatments provided in TAU), blinding of
interviewers will obviously not be possible. These inter-
views will be performed by non-blinded research assistants.
All other interviews and questionnaires will be performed
and administered by blinded research assistants.
When conducting an economic evaluation in the
field of mental health, it can be a challenge to provide a
comprehensive account of all the costs and consequences
that are associated with the treatments being compared
and which are relevant under the target perspective [71].
Since relevant costs for BPD include health care costs,
patient and family costs and costs in other sectors, a
societal perspective will be taken. This also prevents
cost shifting to be interpreted as increases or decreases in
costs. The time horizon of three years covers both theduration of the GST treatment as well as a one year
follow-up time period. This enables an investigation into
the stability of treatment outcome over time. In addition,
relevant costs that are incurred once the GST treatment
has ended, which could be a consequence of treatment
outcome, are thus included. To gather data on the societal
costs and consequences that are associated with BPD and
the BPD treatments being compared in this RCT, resource
use in a wide range of health care facilities is taken into
account, whether inpatient or outpatient, including
various health services specialized for mental health
(e.g. contacts with a psychologist or psychiatrist) as well as
more general health care services (e.g. contacts with a GP
or general hospital). Furthermore, costs due to productivity
losses and informal care will be measured to take into
account the fact that costs and consequences have an
impact on society as well as family and friends, respectively.
Lastly, by taking into account various categories of
out-of-pocket expenses that are typically associated with
BPD (e.g. alcohol, tobacco and drug use, impulsive buying,
binge eating) an attempt will be made to measure all
relevant costs that are specifically associated with BPD.
Despite the extensive effort that is put into obtaining a
complete picture of the costs and consequences that are
associated with BPD and the BPD treatments being
compared in this RCT, it remains unfeasible to include
some particular aspects. For instance, to date no instru-
ments exist to measure the high burden that BPD patients
can impose upon colleagues and organizations due to
suboptimal functioning at work [72]. Also, leisure time is
relevant to patients with BPD, but it can be difficult to
measure and value. Therefore, these aspects are not taken
into account as costs or consequences in the economic
evaluation.
Another degree of complexity is added to economic
evaluations in the field of mental health, as opposed to
somatic disorders, due to the fact that once costs and
consequences are measured, their interpretation can be
difficult. No consensus exists on the extent to which
particular costs need to be included or not and how they
need to be valued [73]. For example, although informal
care provided by family and friends is very relevant to
patients with BPD, it can be difficult to know which
amount of care is specifically due to mental health prob-
lems and which amount they would have received anyway.
Similarly, productivity losses can be the result of being
under treatment, yet patients with mental health problems
are also less likely to be employed or could have already lost
their job before having their diagnosis [74]. Furthermore,
although the volumes of production losses in paid work,
voluntary work, study, and household activities as well as
contacts with the GP and medication use are explicitly
measured separately for being BPD-related or not, this
division cannot always be reliably made. For example, a leg
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but less so when it is the result of a suicide attempt. In such
cases, the analyst is guided by the information provided,
while at the same time being aware that this information
may or may not be complete. In cases where there is suffi-
cient information to attribute a somatic complaint to an
underlying mental health complaint, patient answers are
overruled. Reliability can also be an issue when rather high
out-of-pocket expenses are reported [72].
In addition to the evaluation of clinical effectiveness and
the economic evaluation, a series of additional investiga-
tions will be performed in this RCT that consist of an
assessment of the integrity of GST, in terms of adherence
to the GST protocol, an investigation into the opinions of
major stakeholders and analyses of variables that might
mediate treatment response. The qualitative data on the
experiences of patients and therapists are considered as
complementary to the quantitative methods that will be
employed in this study. By interviewing patients and
therapists, potentially important, yet unanticipated, issues
may be detected. Furthermore, this type of data collection
can give valuable insight into the contextual factors
that play a role in the effectiveness of GST and its
implementation.
Conclusion
GST holds much promise as a treatment for BPD. How-
ever, since only two small studies have tested GST import-
ant questions remain to be answered before its further
implementation is supported. The current international,
multicentre RCT is designed to reveal how GST, when
delivered as a complete and stand-alone treatment by
therapists who were not involved in its development, com-
pares to up-to-date TAU. Concurrently, this RCT aims to
investigate the optimal format for the delivery of GST;
whether consisting almost exclusively of group sessions or
as a combination of individual and group sessions.
In addition to an investigation of clinical effectiveness, this
international multicentre RCT will involve an economic
evaluation to investigate how GST compares to TAU, and
how both formats for GST compare in both clinical and
economic terms. Furthermore, a series of additional investi-
gations will be performed to shed light on the qualitative
aspects of GST and on variables that influence treatment
outcome. In sum, this RCT contributes to an evidence-
based understanding that will inform decisions regarding
which treatment to offer to patients with BPD, both from a
clinical and societal perspective.Additional file
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